Glenmark Pharmaceuticals and FDC Ltd are withdrawing products in the US due to manufacturing problems, as per USFDA reports.

VS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per ...

Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss ...

KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1768 in ...

Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared ...

We expect our North America business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable ...

Glenmark Pharmaceutical Ltd.'s shares rose over 5% during trade on Monday, after the management highlighted a 300.2% sales ...

As the market opens for a new trading day, here are some stocks that are in focus. From BHEL’s new contract to Glenmark ...

The revenue from operations at Glenmark Pharma during Q3FY25 also marked a 35.1 per cent year-on-year (YoY) rise to Rs ...

Glenmark Pharmaceuticals Ltd revenue from operations jumped 35.1% year-on-year to ₹3,387.6 crore, vs ₹2,506.7 crore during Q3 ...

Glenmark Pharmaceuticals rose 5.7% after the company reported a 300.2% sales growth in India for the third quarter.

Pharma stocks experienced significant declines due to concerns over new tariffs. Notably, Dr Reddy's, Zydus Lifesciences, and Aurobindo Pharma saw the largest drops. US President Donald Trump's ...